BindingDB

The first public molecular recognition database, BindingDB supports research, education and practice in drug discovery, pharmacology and related fields.

BindingDB contains 3.2M data for 1.4M Compounds and 11.4K Targets. Of those, 1.5M data for 737K Compounds and 4.7K Targets were curated by BindingDB curators. BindingDB is a FAIRsharing resource.

If BindingDB was of value to your research, please take a moment to donate to this nonprofit project. Your donation will let us provide you with more data and improved service.

Donate Now

To help with training and testing AI and other models, BindingDB downloads and search results now provide the publication date and BindingDB curation date of each measurement.

Advanced Search

12 articles for M Shirouzu

The following articles (labelled with PubMed ID or TBD) are for your review

PMID
Data
Article Title
Organization
Structure-based development of novel substrate-type G9a inhibitors as epigenetic modulators for sickle cell disease treatment.EBI
Kyorin Pharmaceutical Co. Ltd.
Discovery of Novel Substrate-Competitive Lysine Methyltransferase G9a Inhibitors as Anticancer Agents.EBI
Kyorin Pharmaceutical
Structure-Activity Relationship and EBI
Riken Center For Biosystems Dynamics Research
Design and Synthesis of Tranylcypromine-Derived LSD1 Inhibitors with Improved hERG and Microsomal Stability Profiles.EBI
Riken Center For Sustainable Resource Science
Novel bicyclic pyrazoles as potent ALK2 (R206H) inhibitors for the treatment of fibrodysplasia ossificans progressiva.EBI
Riken Center For Sustainable Resource Science
Discovery of Novel Spiroindoline Derivatives as Selective Tankyrase Inhibitors.EBI
Riken
Design and Discovery of an Orally Efficacious Spiroindolinone-Based Tankyrase Inhibitor for the Treatment of Colon Cancer.EBI
Japanese Foundation For Cancer Research
Characterization of crystal water molecules in a high-affinity inhibitor and hematopoietic prostaglandin D synthase complex by interaction energy studies.EBI
Riken Center For Biosystems Dynamics Research
Identification of pyrrolo[2,3-d]pyrimidines as potent HCK and FLT3-ITD dual inhibitors.EBI
Riken Center For Life Science Technologies
Activity cliff for 7-substituted pyrrolo-pyrimidine inhibitors of HCK explained in terms of predicted basicity of the amine nitrogen.EBI
Riken Center For Life Science Technologies
Oxazole orexin receptor antagonistsBDB
Merck Sharp & Dohme